A rapid, sensitive, and specific method was developed and validated using ultra-performance liquid chromatographytandem mass spectrometry (UPLC-MS-MS) for simultaneous determination of clozapine and its major metabolite norclozapine in human serum. The compounds were extracted from serum by a single step protein precipitation and analyzed using a UPLC-triplequadrupole detection (TQD) system. Separation of compounds was achieved on a BEH C18 (50 mm × 2.1 mm, 1.7 µm) analytical column using methanol and water (both containing 0.2% ammonium hydroxide) as the mobile phase at a flow rate of 0.40 mL/min. The compounds were ionized in the electrospray ionization ion source of the TQD and were detected in the multiple reaction monitoring ( 
Introduction
Clozapine, a tricyclic dibenzodiazepine derivative ( Figure  1 ), was developed in the 1960s as the first atypical antipsychotic drug with activity against schizophrenia (1) (2) (3) (4) . In 1975, after reports of agranulocytosis leading to death in some clozapine-treated patients, clozapine was voluntarily withdrawn by the manufacturer and fell out of favor for more than a decade. However, scientific research eventually showed that agranulocytosis only occurred in 1-2% of treated patients, and it could be detected early by monitoring hematology parameters. Further studies confirmed that clozapine was more effective against the negative sympotoms of schizophrenia and resulted in a lower incidence of tardive dyskinesia than using traditional antipsychotics. In 1989, the United States Food and Drug Administration (FDA) and the health authorities of most other counties approved clozapine for the treatment of patients with schizophrenia who failed to show an acceptable response to other available therapies, but its use required weekly blood testing. In 2002, the FDA also approved a new indication for the schizophrenia drug Clozaril (clozapine) to reduce the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder (5) (6) (7) (8) (9) (10) (11) (12) (13) .
Besides agranulocytosis, clozapine may induce other side effects, such as tonic clonic, myoclonic, atonic, or partial seizures. The mean dosage of clozapine associated with seizures is less than 600 mg daily (14) . Clozapine is also known to cause weight gain and is associated with drug-induced fever. Cytokines have been linked to both of the side effects (15) . New warnings about serious side effects of clozapine have recently been issued. Analysis of post-marketing safety databases suggests that clozapine is associated with an increased risk of myocarditis, insulin resistance, diabetes, and hyperglycemia (high blood sugar), especially during, but not limited to, the first month of therapy (16) .
Clozapine is extensively metabolized in the liver and converted into several metablolites by oxidative cytochrome P450 isoenzyme 1A2. The major metabolite, norclozapine (desmethylclozapine), is also pharmacologically active; however, it has lower potency than the parent drug clozapine (17) (18) (19) . Studies have also provided evidence that toxic side effects may be associated with clozapine metabolites (20) . The level monitoring of clozapine and its metabolites is useful in assisting clinicians in monitoring and managing the risks of side effects. Clozapine and its major metabolite desmethylclozapine have to be routinely monitored in patient sera during therapeutic treatment.
Several methods for determining clozapine concentrations in serum and plasma using gas chromatography (GC) (21), GC-mass spectrometry (MS), high-performance liquid chromatography (HPLC) (18) , and LC-MS-MS (3, 22, 23) together with different extraction procedures have been published. However, none of them used an ultra-performance (UP) LC system. In this paper, we describe the development and validation of a simple, accurate, and reproducible UPLC-MS-MS method for the simutaneous determination of clozapine and norclozapine in human serum.
Experimental

Reagents and standards
Clozapine and internal standard (IS) clozapine-d 8 were purchased from Cerilliant (Round Rock, TX). Norclozapine was obtained from Sigma-Aldrich Canada (Oakville, ON, Canada). Standard compounds were stored according to supplier recommendations. Control serum was provided by Valley Biomedical (Winchester, VA). HPLC-grade methanol, isopropanol, and acetonitrile (Fisher Scientific Canada, Ottawa, ON, Canada) were used for the preparation of mobile phase and exaction. LC-MS-grade ammonium hydroxide solution and formic acid were purchased from Sigma-Aldrich Canada. The ultra-pure water (18.2 M) used was from Millipore Ultra-Pure Water System. Ultra-pure argon gas (argon 1006, > 99.999%) was used as collision gas and obtained from Praxair Canada.
Instrumentation
A Waters ACQUITY TQD UPLC-MS system (Waters, Mississauga, ON, Canada), consisting of a sample manager, a binary solvent manager, a column manager, a photodiode-array (PDA) detector, and a triple-quadrupole (TQD) tandem MS, was used in this investigation. MS control and spectral processing were carried out using MassLynx software (version 4.1).
Methods
UPLC-MS-MS conditions
The analytes were separated on a Waters ACQUITY UPLC system using a 2.1 × 50-mm ACQUITY BEH C18 column with a flow rate of 0.4 mL/min. Mobile phases A and B were water and methanol, respectively, and both contained 0.2% ammonium hydroxide. Strong wash solution consisted of isopropanol, methanol, and formic acid (50:50:0.2), and weak wash solution was methanol and water (30:70). Five microliters of each sample was injected into the column. The column and autosampler temperatures were held at 45°C and 20°C, respectively. The separation and elution gradient were set at the parameters listed in Table I. MS was performed using a TQD equipped with an electrospray ionization (ESI) source. Positive ionization was used in the multiple reaction monitoring (MRM) mode, with two transitions for each compound. The dwell time used was 0.03 s. The capillary voltage was set to 1.0 kV. The source and desolvation temperatures were optimized and kept at 150°C and 400°C, respectively. The desolvation gas was delivered at a flow rate of 800 L/h and the cone gas was set to 50 L/h. The pressure of collision gas (Argon) was maintained at 7 psi. The appropriate MRM transitions, cone voltages, and collision energies were obtained by using intelliStart "Sample Tune" with "combined" mode, which combined the infusion (10 µL/min) and LC flow (0.4 mL/min) into the MS together.
The precursor to product ion transitions along with the cone voltage and collision energy for each standard and internal standard are as follows: m/z 327. . The target ion response ratio acceptability range was established as ± 20% relative of the mean value of the product ion ratios obtained from the calibrators. System operation and data acquisition were controlled using MassLynx 4.1 software. Analytes were identified by comparing the retention times and the MRM transitions with those of the corresponding calibrators and quality control (QC) samples. Data were processed with the TargetLynx program using the peakarea ratio for quantification. Preparation of standards and QC solutions The stock solution of clozapine was prepared by diluting the standard solution (Cerilliant, 1 mg/mL) in methanol to obtain final drug concentration of 200 µg/mL. The stock solution of norclozapine (200 µg/mL) was prepared by dissolving an appropriate amount of drug in methanol. Serum was spiked with stock solution of the two drugs to achieve the following calibration standard concentrations: 10, 20, 50, 100, 400, 1000, and 2000 ng/mL. QC samples, with the concentrations of 30, 600, and 1600 ng/mL, were prepared in the same way and were run in each assay. Stock IS was prepared by dissolving 1 mg of clozapine-d 8 in 10 mL of acetonitrile. The working IS was prepared by accurate dilution of the stock IS with acetonitrile to get a final concentration of 5000 ng/mL. A 10-µL volume of working IS was added to 0.5-mL serum samples. All of the stock solution was stored at -20°C. Serum standard calibrators were prepared for each day of analysis or validation.
Sample collection and pretreatment
The blood samples of the patients who were treated with clozapine were collected into 6-mL Greiner Vacuette chemistry serum evacuated tubes (Fisher) in the morning approximately 12 h after the last dose and just before the next morning dose. The blood samples were allowed to clot for at least 30 min and then centrifuged for 10 min. The sera were immediately transferred into the labeled 12 × 75-mm aliquot tubes and sealed. All the serum samples were stored at -20°C until analysis.
Extraction procedure and sample preparation
Clozapine and norclozapine were extracted from the serum samples by a simple one-step extraction procedure. First, aliquots of 0.5 mL of standard curve, QC, and unknown serum samples were prepared in 2-mL microcentrifuge tubes, then 10 µL of working IS was sequentially added into the sample tubes. The final concentration of IS in the serum was held at 100 ng/mL. The serum samples were precipitated by adding 1 mL of acetonitrile, then vortex mixing for 30 s, and after that, centrifuging at 13,000 rpm (18°C) for 10 min. The supernatants of samples were diluted with mobile phase (1:1) and transferred to the HPLC vials. Five microliters was injected into the UPLC-MS-MS system for the analysis.
Method Validation Calibration curve and quantification
The seven-point standard curve was established on the basis of the peak-area ratios of the analytes relative to the IS. The linearity of the standard concentrations ranging from 10 to 2000 ng/mL (10, 20, 50, 100, 400, 1000, and 2000 ng/mL) in human serum was analyzed using the previously described UPLC-MS-MS method. Standard response curve generated using weighted (1/x) linear regression model. The concentrations of clozapine and norclozapine in unknown serum samples from schizophrenic patients were calculated by comparing their peak-area ratios (analyte/IS) with those of the calibration curve standards. The IS was clozapine-d 8 .
Lower limit of quantification (LLOQ) and limit of detection (LOD)
The LLOQ in the MRM mode was defined as the lowest point of the calibration curve (concentration 10 ng/mL) and fulfilled the requirement of LLOQ signal-to-noise ratio of 10:1. The human serum samples spiked with decreasing concentrations of the analytes (clozapine and norclozapine) and with same amount of the IS were analyzed in order to determine the LODs. The LOD was set at the lowest concentration where the signals of compounds were three times higher than the background noise. The LOQs were determined by measuring six samples per concentration for both compounds.
Accuracy and precision
The accuracy and precision of the method was assessed by the determination of intraday and interday assay variations. QC samples were prepared at three concentration levels, 30 ng/mL (LOW), 600 ng/mL (MED), and 1600 ng/mL (HIGH). They were analyzed according to the procedure described in the preceding text on each of the 20 days. The concentrations of the analytes in QC samples were calculated via the daily calibration curves. The deviations of QC samples were used to assess the accuracy (bias) of the method. Intraday precision was evaluated by replicate (n = 20) analysis of QC samples in one run. Interday precision was determined by replicate (n = 6) analysis of QC samples in 20 experiments performed at different days. Precision data given as percentage of coefficient of variation (CV %) for intraday (repeatability) and interday (run) precisions of the method were calculated. The acceptance intervals of intraday and interday precision were within 15% (within 20% at LLOQ) of nominal values. Accuracy was within 15% (within 20% at the LLOQ) of nominal values.
Extraction recovery
Two sets of standards of clozapine and norclozapine were prepared and each set contained four concentrations of both compounds (30, 100, 600, and 2000 ng/mL). Set 1 was prepared by using blank human serum spiked with analytes before the extraction (n = 6), and then were treated as the previous mentioned extraction method. After extraction, 10 µL of working IS was added into each standard solution. Set 2 was obtained by adding the analytes and IS to the extracted solution of serum after the extraction procedure (n = 6). The extraction recovery was calculated by comparing peak-area ratios of analytes/IS in the samples of sets 1 and 2. Extraction recovery (%) = (concentration measured from set 1/concentration measured from set 2) × 100.
Results and Discussion
UPLC-MS-MS
The column temperature was set at 45°C in order to reduce the pressure of the column and improve resolution. Five microliters of extracted solution was injected for the analysis. The TQD in the MRM mode provided a highly selective and sensitive method for the determination of the clozapine and norclozapine, and their retention times were approximately 1.32 and 1.22, respectively. The MRM chromatograms of negative control human serum showed no transition peaks of either clozapine or norclozapine. The MRM chromatograms of the standards (each 10 ng/mL) in control serum are provided in Figure 2 .
Linearity and sensitivity
The concentration range was 10-2000 ng/mL for both clozapine and norclozapine. Their calibration curves showed good linear response. The correlation coefficients (r 2 ) of the curves obtained on multiple days were consistently > 0.997 for both clozapine and norclozapine. The LODs were 15 and 10 pg/mL for clozapine and norclozapine, respectively [signal-to-noise (S/N) > 3]. The LLOQ was defined as the lowest point of the calibration curve, which was 10 ng/mL. An S/N > 10 at the LLOQ was observed for both compounds.
Accuracy, precision, and recovery
Results of accuracy and intra-and interday precision studies are presented in Table II . Interassay CVs (n = 20) were 3.04-4.94% for clozapine and 2.84-6.07% for norclozapine. Intra-assay CVs (n = 6, 20 days) were 0.61-1.26% and 1.62-2.21% for clozapine and norclozapine, respectively. The extraction recoveries are shown in Table III . The average extraction recoveries were greater than 95% for both clozapine and norclozapine.
Post-run stability
For estimation of the stability of the processed samples under the conditions of UPLC-MS-MS analysis, two QC samples (low and high, n = 6) were extracted as described in the previous section. The extracts were transferred into the UPLC vials and determined using the standard curve calibration described in this article. The QC samples were analyzed again using a new standard curve after 24 h loaded into the autosampler. Our experiment showed there was no significant difference between the results of two days (Table IV) . Clozapine and norclozapine were stable for 24 h within the autosampler.
Freeze-and-thaw stability
For evaluation of the freeze-and-thaw stability, three QC samples (n = 6, each) were analyzed after three freeze-and-thaw cycles. For each freeze-and-thaw cycle, the samples were frozen at -20°C for 24 h, thawed, and kept at ambient temperature for 2 h. The mean concentrations deviated from the actual value by no more than 3% for both clozapine and norclozapine. It was concluded that there was no loss of clozapine and norclozapine during the three freeze-and-thaw cycles (Table IV) .
Long-term stability
The experimental design and procedure for evaluation of long-term stability were similar to those used in the freezeand-thaw stability. Analyte stability in long-term storage was tested by analyzing three QC samples (n = 6, each) after storing at -20°C for 1 month. The obtained data showed no significant change for the concentrations of clozapine and norclozapine. The results are summarized in Table IV .
Short-term room temperature stability
Two QC samples (low and high, n = 6) were thawed at room temperature for 6 h and then analyzed. The results showed that the serum samples containing clozapine and norclozaine were stable within 6 h (Table IV) . 
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Analysis of the serum of patients
The serum samples were obtained from 20 patients with schizophrenia, in which the serum levels were routinely monitored for adjusting the dose of clozapine to achieve the optimal clinical effect. The concentrations of clozapine and norclozapine determined by the method are shown in Table V .
Conclusions
A UPLC-MS-MS method has been developed and validated for the determination of clozapine and norclozapine in the serum samples. The therapeutic reference range for clozapine is 100-600 ng/mL, and clozapine may be toxic if the concentration is higher than 900 ng/mL. We set up the concentration of LLOQ at 10 ng/mL for both clozapine and norclozapine and used 0.5 mL of serum for the analysis. The extraction used a one-step acetonitrile extraction and precipitation. An ACQUITY UPLC BEH C18 column was designed to perform the separation in a wide pH range. We obtained good separation for clozapine and norclozapine by using 0.2% ammonium hydroxide in the mobile phases. In comparison with normal HPLC-MS-MS, UPLC-MS-MS shortened the analysis time and simplified the preparation of the sample. The method described here was found to be simple, specific, and accurate for the simultaneous determination of clozapine and its major metabolite norclozapine in the sera of schizophrenic patients. 
